Recent Advances in the Physiological Functions and Biosynthesis of D-Allulose

Read this before you formulate your next low-sugar product

D-allulose is often treated as a bulk sweetener. That misses the bigger picture. A review published in Frontiers in Microbiology (DOI: 10.3389/fmicb.2022.881037) compiles the current evidence on what D-allulose does in the body and how it can be made. If you source sweeteners or build formulations, this paper is worth your time.

Background: a sweetener with drug-like potential

The review covers two broad areas. First, the physiological effects of D-allulose. Second, the latest biosynthesis routes. The authors start from a simple position. D-allulose is not just a sweetener. It is a functional carbohydrate.

The physiological list is impressive. D-allulose shows anti-obesity activity. It lowers blood glucose. It has anti-diabetic effects. It also demonstrates anti-inflammatory, antioxidant, and neuroprotective activity. That goes far beyond taste.

What the study did

This is a review paper, not a new clinical trial. The authors organized recent work on D-allulose and focused on two biosynthesis strategies. One is the Izumoring strategy. The other uses DHAP-dependent aldolases.

Both routes matter for production. The Izumoring strategy is a well-known enzymatic approach for creating rare sugars. The DHAP-dependent aldolase strategy offers a different path. For ingredient buyers, that means more options for sourcing and scale.

Key evidence at a glance

The most concrete human data point in the review involves a simple test. Researchers gave normal adults 5 g of D-allulose along with 75 g of maltodextrin. The D-allulose significantly suppressed the blood glucose spike. That is a small dose. It is a realistic dose for a food or beverage serving.

Here is what the review reports:

Function	Reported effect
Anti-obesity	D-allulose has anti-obesity activity
Blood glucose control	5 g D-allulose suppresses the glucose rise from 75 g maltodextrin in normal adults
Anti-diabetic	D-allulose shows anti-diabetic effects
Anti-inflammatory	D-allulose has anti-inflammatory activity
Antioxidant	D-allulose acts as an antioxidant
Neuroprotection	D-allulose protects neurons

These are general conclusions from reviewed studies. The 5 g vs 75 g finding stands out. It gives formulators a specific reference point.

What this means for manufacturers

You can reposition D-allulose in your product portfolio. Instead of selling it as a sweetener that simply does what sugar does, you can highlight its functional benefits. A formulation with 5 g per serving has scientific support for blood glucose control. That is valuable in the diabetic-friendly and low-glycemic food categories.

The biosynthesis review matters for a different reason. More production routes mean less dependence on a single process. That should reassure buyers who worry about raw material constraints.

Still, keep the evidence in perspective. The human evidence highlighted in the abstract is narrow. The review does not claim that 5 g of D-allulose cures diabetes. It shows a measurable glucose response. That is enough to justify product concepts, but not enough to make disease claims.

FAQ

How much D-allulose showed a blood glucose effect? 5 g per intake. In normal adults, that dose significantly blunted the glucose response to 75 g of maltodextrin.

What are the two biosynthetic routes covered? The Izumoring strategy and the DHAP-dependent aldolase strategy. Both offer paths to D-allulose, and the review explains their recent progress.

Should I wait for more human data before using D-allulose? You can already formulate with D-allulose. The 5 g human finding is a solid starting point. Just be careful not to overstate the results.

The bigger opportunity

D-allulose is more than a sugar mimic. The science shows a range of physiological effects, and the production toolkit is expanding. For food formulators, the smart move is to plan around the 5 g dose that moved the glucose needle. For ingredient buyers, the smart move is to track both biosynthesis strategies. The next few years will decide which route wins at scale.